Sotirios Tsimikas
#124,623
Most Influential Person Now
Researcher
Sotirios Tsimikas's AcademicInfluence.com Rankings
Sotirios Tsimikasengineering Degrees
Engineering
#4047
World Rank
#5204
Historical Rank
Cybernetics
#57
World Rank
#63
Historical Rank
Biomedical Engineering
#231
World Rank
#238
Historical Rank
Applied Physics
#895
World Rank
#917
Historical Rank
Download Badge
Engineering
Sotirios Tsimikas's Degrees
- PhD Biomedical Engineering University of California, San Diego
- Masters Electrical Engineering University of California, San Diego
- Bachelors Electrical Engineering University of California, San Diego
Why Is Sotirios Tsimikas Influential?
(Suggest an Edit or Addition)Sotirios Tsimikas's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. (2005) (698)
- A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. (2017) (570)
- Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity (2011) (562)
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials (2016) (516)
- Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses (2012) (485)
- Complement factor H binds malondialdehyde epitopes and protects from oxidative stress (2011) (479)
- Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. (2010) (410)
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides (2017) (398)
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study (2015) (376)
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. (2020) (371)
- Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. (2003) (370)
- Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. (2003) (348)
- C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. (2006) (346)
- Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans (2016) (316)
- Oxidized Phospholipids are Proinflammatory and Proatherogenic in Hypercholesterolemic Mice (2018) (307)
- Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials (2018) (281)
- NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. (2018) (276)
- Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. (2015) (270)
- Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. (2011) (264)
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. (2019) (257)
- Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events Published, JLR Papers in Press, November 8, 2006. (2007) (248)
- Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study (2007) (248)
- Human-Derived Anti-Oxidized LDL Autoantibody Blocks Uptake of Oxidized LDL by Macrophages and Localizes to Atherosclerotic Lesions In Vivo (2001) (231)
- Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a): Short-Term and Long-Term Immunologic Responses to Oxidized Low-Density Lipoprotein (2004) (229)
- Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. (2014) (223)
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. (2020) (220)
- Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. (2012) (211)
- Statin therapy increases lipoprotein(a) levels. (2020) (202)
- High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial (2004) (201)
- Adaptive immunity in atherogenesis: new insights and therapeutic approaches. (2013) (188)
- Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. (2012) (183)
- Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis (2014) (182)
- Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. (2006) (179)
- Deficiency of Glutathione Peroxidase-1 Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice (2007) (178)
- Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. (2011) (171)
- Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor–Deficient Mice (2001) (171)
- Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes (2008) (165)
- The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. (2014) (155)
- Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)1 (2013) (151)
- Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease (2006) (150)
- Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. (2001) (149)
- Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia: Results of 4 Phase III Trials (2015) (148)
- Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. (2010) (145)
- Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis (2019) (145)
- Lipoprotein(a) for risk assessment in patients with established coronary artery disease. (2014) (144)
- Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. (2011) (142)
- Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo (1999) (142)
- Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III (2017) (140)
- Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. (2008) (138)
- Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice (2008) (138)
- Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis (2017) (137)
- Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial. (2009) (137)
- Common femoral artery anatomy is influenced by demographics and comorbidity: Implications for cardiac and peripheral invasive studies (2001) (136)
- Apolipoprotein C-III: From Pathophysiology to Pharmacology. (2015) (135)
- New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A2 in Atherosclerosis and Cardiovascular Disease (2007) (135)
- Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. (2008) (134)
- Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease: The EPIC-Norfolk Prospective Population Study (2012) (133)
- Lysine-Phosphatidylcholine Adducts in Kringle V Impart Unique Immunological and Potential Pro-inflammatory Properties to Human Apolipoprotein(a)* (2003) (130)
- Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia (2020) (130)
- Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study (2011) (129)
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels (2019) (125)
- In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. (2000) (125)
- The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity (2008) (123)
- ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering (2015) (122)
- The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. (2008) (122)
- Advanced Glycation End Products and Diabetic Cardiovascular Disease (2012) (121)
- LDL isolated from Greek subjects on a typical diet or from American subjects on an oleate-supplemented diet induces less monocyte chemotaxis and adhesion when exposed to oxidative stress. (1999) (119)
- B-Cell Aortic Homing and Atheroprotection Depend on Id3 (2012) (118)
- Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. (2006) (118)
- Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. (2002) (116)
- Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. (2010) (115)
- Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. (2011) (114)
- Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. (2011) (113)
- Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). (2014) (112)
- Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans (2016) (112)
- B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. (2015) (111)
- Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors: Results From the Dallas Heart Study (2009) (111)
- Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. (2011) (106)
- Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions (2012) (105)
- Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up (2017) (104)
- Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial (2019) (103)
- Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States (2016) (97)
- Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. (2016) (97)
- PCSK9 Association With Lipoprotein(a). (2016) (96)
- Imaging vulnerable plaque by ultrasound. (2006) (93)
- The role of innate immunity in atherogenesis11 Guest editor for this article was Linda Curtiss, the Scripps Research Institute. Published, JLR Papers in Press, December 22, 2008. (2009) (91)
- Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. (2008) (90)
- Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. (2019) (90)
- Invasive Cardiologists Are Exposed to Greater Left Sided Cranial Radiation: The BRAIN Study (Brain Radiation Exposure and Attenuation During Invasive Cardiology Procedures). (2015) (89)
- Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. (2015) (88)
- Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. (2006) (88)
- Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Choleste (2009) (87)
- Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. (2011) (86)
- In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. (2011) (86)
- Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. (2014) (85)
- Oxidized Cholesteryl Esters and Phospholipids in Zebrafish Larvae Fed a High Cholesterol Diet (2010) (83)
- Lipid-Lowering Agents. (2019) (82)
- In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. (2016) (81)
- Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies1[S] (2015) (81)
- Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. (2013) (80)
- Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. (2006) (80)
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1 (2016) (79)
- Immune cell screening of a nanoparticle library improves atherosclerosis therapy (2016) (79)
- Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. (2006) (79)
- Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). (2016) (79)
- Oxidized low-density lipoprotein biomarkers in atherosclerosis (2006) (79)
- MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma (2013) (78)
- Secretory Phospholipase A2-IIA and Cardiovascular Disease (2013) (78)
- Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. (2007) (78)
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial (2020) (78)
- LPA Gene, Ethnicity, and Cardiovascular Events (2017) (78)
- Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression (2007) (77)
- Molecular Imaging of Matrix Metalloproteinase Expression in Atherosclerotic Plaques of Mice Deficient in Apolipoprotein E or Low-Density-Lipoprotein Receptor (2009) (77)
- Reduced In Vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilization (2004) (76)
- Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. (2006) (75)
- Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. (2013) (73)
- In vivo markers of oxidative stress and therapeutic interventions. (2008) (72)
- The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal? (2013) (72)
- In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. (2012) (71)
- Oxidation-specific biomarkers and risk of peripheral artery disease. (2013) (71)
- Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. (2009) (71)
- Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease (2016) (70)
- Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. (2012) (69)
- Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet (2010) (69)
- The Oxidative Modification Hypothesis of Atherogenesis (2000) (67)
- Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages (2018) (67)
- Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance (2016) (65)
- Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)[S] (2015) (65)
- Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients (2017) (65)
- Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience (2019) (64)
- Emerging therapeutic agents to lower lipoprotein (a) levels (2012) (63)
- Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities (2020) (62)
- Lipoprotein(a)-Associated Molecules Are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis (2017) (62)
- Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. (2012) (61)
- Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis (2018) (60)
- Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. (2010) (59)
- Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial (2018) (59)
- Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation (2020) (58)
- Statin‐Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction (2006) (57)
- Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. (2002) (56)
- Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes (2012) (55)
- Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. (2015) (54)
- Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study (2017) (54)
- Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia1 (2012) (53)
- Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis (2016) (53)
- Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature (2017) (52)
- Reduction of myocardial ischaemia–reperfusion injury by inactivating oxidized phospholipids (2019) (51)
- In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes. (2012) (51)
- Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. (2018) (50)
- High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. (2005) (50)
- Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism Is Associated With Progressive Atherosclerosis and Incident Cardiovascular Disease (2015) (50)
- Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis. (2019) (50)
- Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study (2017) (49)
- The role of dietary fatty acids in lipoprotein oxidation and atherosclerosis. (1998) (49)
- The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans (2017) (48)
- RNA-targeted therapeutics for lipid disorders (2018) (48)
- Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (2021) (48)
- Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. (2018) (47)
- Measures of oxidative stress. (2006) (47)
- Helix-Loop-Helix Factor Inhibitor of Differentiation 3 Regulates Interleukin-5 Expression and B-1a B Cell Proliferation (2013) (46)
- Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements (2021) (46)
- Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk (2016) (45)
- Polyoxygenated Cholesterol Ester Hydroperoxide Activates TLR4 and SYK Dependent Signaling in Macrophages (2013) (45)
- Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. (2021) (45)
- Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis (2020) (44)
- Spontaneous coronary artery dissection in patients with renal transplantation. (1999) (44)
- Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine1[S] (2014) (43)
- Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a) (2020) (43)
- PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis. (2018) (42)
- Renal frame count and renal blush grade: quantitative measures that predict the success of renal stenting in hypertensive patients with renal artery stenosis. (2008) (40)
- The dedicated "Lp(a) clinic": A concept whose time has arrived? (2020) (40)
- Transcatheter closure of patent foramen ovale for migraine prophylaxis: hope or hype? (2005) (39)
- Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. (2013) (39)
- From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. (2020) (38)
- Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study (2015) (38)
- New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis. (2014) (36)
- ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance[S] (2019) (36)
- Diversification and CXCR4-Dependent Establishment of the Bone Marrow B-1a Cell Pool Governs Atheroprotective IgM Production Linked To Human Coronary Atherosclerosis. (2019) (35)
- Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. (2017) (35)
- Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. (2005) (34)
- Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis (2016) (34)
- Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events (2017) (34)
- Oxidation-specific epitopes restrain bone formation (2018) (33)
- Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. (2012) (32)
- The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. (2010) (32)
- Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. (2005) (31)
- Peptide mimotopes of malondialdehyde-epitopes for clinical applications in cardiovascular disease (2015) (31)
- Influence of beta-adrenergic stimulation and contraction frequency on rat heart interstitial adenosine. (1990) (30)
- Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. (2017) (30)
- The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). (2017) (30)
- Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data (2020) (29)
- Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR(-/-) and ApoE(-/-) mice. (2012) (29)
- Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device: is it a suture device or a "stent"? (2004) (29)
- Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms. (2017) (29)
- Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics (2013) (28)
- Imaging of Oxidation-Specific Epitopes in Atherosclerosis and Macrophage-Rich Vulnerable Plaques (2010) (28)
- The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) (2017) (28)
- Fibromuscular dysplasia of renal arteries: Percutaneous revascularization based on hemodynamic assessment with a pressure measurement guidewire (2006) (27)
- Identification of a novel series of anti-inflammatory and anti-oxidative phospholipid oxidation products containing the cyclopentenone moiety in vitro and in vivo: Implication in atherosclerosis* (2017) (27)
- Treatment of recurrent pulmonary vein stenoses with endovascular stenting and adjuvant oral sirolimus (2007) (27)
- Threshold Effects of Circulating Angiopoietin‐Like 3 Levels on Plasma Lipoproteins (2017) (26)
- Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction (2016) (26)
- Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography (2019) (26)
- Non‐invasive imaging of vulnerable plaques by molecular targeting of oxidized LDL with tagged oxidation‐specific antibodies (2002) (25)
- Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. (2022) (25)
- Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study1 (2016) (24)
- Manganese G8 dendrimers targeted to oxidation‐specific epitopes: In vivo MR imaging of atherosclerosis (2015) (24)
- Lipid Oxidation in Carriers of Lecithin: Cholesterol Acyltransferase Gene Mutations (2012) (24)
- The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. (2012) (24)
- What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis? (2014) (23)
- ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis (2020) (22)
- The re-emergence of lipoprotein(a) in a broader clinical arena. (2016) (22)
- Subintimal wire position during angioplasty of a chronic total coronary occlusion: detection and subsequent procedural guidance by intravascular ultrasound. (1995) (21)
- microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production (2020) (21)
- Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. (2007) (21)
- Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels—Brief Report (2020) (21)
- Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis[S] (2019) (20)
- Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century. (2002) (20)
- Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events (2020) (19)
- New Insights Into the Role of Lipoprotein ( a )-Associated Lipoprotein-Associated Phospholipase A 2 in Atherosclerosis and Cardiovascular Disease (2007) (19)
- Statins and increases in Lp(a): an inconvenient truth that needs attention. (2019) (17)
- Successful utilization of a novel aspiration thrombectomy catheter (Pronto) for the treatment of patients with stent thrombosis (2006) (17)
- Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin. (2011) (17)
- Emerging approaches for imaging vulnerable plaques in patients. (2007) (17)
- Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study (2021) (16)
- The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents. (2008) (16)
- Secretory Phospholipase A2-IIA and Cardiovascular Disease A Mendelian Randomization Study (2017) (16)
- Erratum: Differential expression of oxidation-specifi c epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions (J. Lipid Res. (2012) 53 (2773-2790) (2014) (16)
- IGHV1-69-Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia React with Malondialdehyde–Acetaldehyde Adduct, an Immunodominant Oxidation-Specific Epitope (2013) (16)
- Lipoprotein(a) accelerates atherosclerosis in uremic mice[S] (2010) (16)
- Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions (2014) (16)
- Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk. (2016) (16)
- Prevalence of coronary artery spasm after stent placement and its association with inflammation. (2015) (15)
- Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx (2021) (15)
- Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency (2021) (15)
- ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers (2015) (15)
- Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis (2007) (15)
- Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. (2017) (15)
- INHIBITION OF APOLIPOPROTEIN C-III WITH GALNAC CONJUGATED ANTISENSE DRUG POTENTLY LOWERS FASTING SERUM APOLIPOPROTEIN C-III AND TRIGLYCERIDE LEVELS IN HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES (2018) (15)
- Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia. (2019) (15)
- High-dose statins prior to percutaneous coronary intervention: a paradigm shift to influence clinical outcomes in the cardiac catheterization laboratory. (2009) (14)
- Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (2021) (14)
- Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk (2022) (14)
- Phospholipase A 2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes Aggressive (2012) (14)
- Concomitant coronary and multiple arch vessel stenoses in patients treated with external beam radiation: Pathophysiological basis and endovascular treatment (2004) (14)
- Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina (2016) (13)
- In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes1 (2018) (13)
- Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease[S] (2012) (13)
- Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies Running title : Microparticles carry oxidation-specific epitopes (2014) (12)
- Estrogen-Eluting Stents (2009) (12)
- EFFECT OF MIPOMERSEN ON LIPOPROTEIN(A) IN PATIENTS WITH HYPERCHOLESTEROLEMIA ACROSS FOUR PHASE III STUDIES (2012) (12)
- The challenges of measuring Lp(a): A fight against Hydra? (2019) (12)
- Intracellular AIBP (Apolipoprotein A-I Binding Protein) Regulates Oxidized LDL (Low-Density Lipoprotein)-Induced Mitophagy in Macrophages. (2020) (12)
- OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients. (2011) (12)
- Plasma Proteomics for Epidemiology: Increasing Throughput With Standard-Flow Rates (2017) (12)
- Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling: Adding the Plasminogen Receptor PlgRKT to the List. (2017) (11)
- Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. (2022) (11)
- Recent advances in hemodynamics (2008) (11)
- Neutralization of oxidized phospholipids attenuates age‐associated bone loss in mice (2021) (11)
- Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease (2018) (11)
- Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis). (2015) (11)
- Treatment of ischemic stroke complicating cardiac catheterization with systemic thrombolytic therapy (2005) (10)
- Expanded applications of rotational atherectomy in contemporary coronary and peripheral interventional practice. (2005) (10)
- PCSK 9 Association With Lipoprotein ( a ) (2016) (9)
- Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. (2021) (9)
- Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. (2018) (9)
- The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting (2017) (9)
- Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice (2018) (9)
- Candidate biomarkers for the detection of coronary plaque destabilization and rupture (2008) (8)
- Inhibition of fructose bisphosphatase and stimulation of phosphofructokinase by a stable isosteric phosphonate analog of fructose 2,6-bisphosphate. (1986) (8)
- The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection (2021) (8)
- Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events (2012) (8)
- Renal artery plaque composition is associated with changes in renal frame count following renal artery stenting. (2011) (8)
- Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. (2022) (8)
- JCL Roundtable: Should we treat elevations in Lp(a)? (2016) (8)
- Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) (2019) (7)
- High-Density Lipoproteins Are the Main Carriers of PCSK9 in the Circulation. (2020) (7)
- A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow‐Fed Young Adult Mice (2020) (7)
- PCSK9 Activity Is Potentiated Through HDL Binding (2021) (7)
- Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly. (2021) (7)
- Catheter-induced Vasospasm of Both the Right External Iliac and Right Coronary Arteries During Coronary Angiography (2005) (6)
- Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a). (2020) (6)
- The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia (2020) (6)
- Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. (2017) (6)
- Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis. (2021) (6)
- The clinical emergence of optical coherence tomography: defining a role in intravascular imaging. (2012) (5)
- The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with FCS (2018) (5)
- Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a) (2020) (5)
- Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOCIII. (2017) (5)
- Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. (2020) (5)
- Coronary Heart Disease Phospholipase A 2 Enzymes , High-Dose Atorvastatin , and Prediction of Ischemic Events After Acute Coronary Syndromes (2012) (5)
- Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease (2022) (5)
- Highlights of the Year in JACC 2005. (2006) (5)
- Spontaneous multivessel coronary vasospasm leading to cardiogenic shock. (2007) (5)
- Highlights of the Year in JACC 2008. (2009) (5)
- Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a) (2022) (5)
- Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. (2022) (5)
- Erratum to “The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med 2012;13:11-9” (2014) (5)
- Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS Studies (2018) (5)
- Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement (2019) (5)
- Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold? (2012) (5)
- Lipoproteins and Oxidation (2006) (4)
- PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults[S] (2019) (4)
- Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls (2019) (4)
- Rat Heart (2005) (4)
- Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. (2022) (4)
- In Search of Patients With Elevated Lp(a): Seek and Ye Shall Find. (2019) (4)
- P265 LIPOPROTEIN(a) ACCELERATES ATHEROSCLEROSIS IN UREMIC MICE (2010) (4)
- chapter 22 – Lipoprotein Oxidation, Macrophages, Immunity, and Atherogenesis (2004) (4)
- A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma1[S] (2018) (4)
- High-level lipoprotein [a] expression in transgenic mice: Published, JLR Papers in Press, January 16, 2005. DOI 10.1194/jlr.M400467-JLR200evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins (2005) (4)
- Lipoprotein(a) and Coronary Calcium: Clinical Management and Potential Design of Primary Prevention Trials. (2022) (3)
- OXIDIZED PHOSPHOLIPIDS ON APOLIPOPROTEIN(A) ARE ONLY PRESENT ON HUMAN LP(A): IMPLICATIONS FOR UNDERSTANDING LP(A) ATHEROGENICS (2013) (3)
- Relationship Between the Heparin Management Test and the HemoTec Activated Clotting Time in Patients Undergoing Percutaneous Coronary Intervention (2001) (3)
- PCSK9 Inhibition and Oxidized Phospholipids. (2021) (3)
- Highlights of the year in JACC 2012. (2013) (3)
- Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis (2022) (3)
- Highlights of the year in JACC 2013. (2014) (3)
- Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice (2018) (3)
- Monday, 27 August 2012 (2012) (3)
- CLINICAL STUDIES Acute Coronary Syndromes Temporal Increases in Plasma Markers of Oxidized Low-Density Lipoprotein Strongly Reflect the Presence of Acute Coronary Syndromes (2003) (3)
- Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity (2021) (3)
- Retrieval of a detached transseptal sheath tip from a right pulmonary artery branch following catheter ablation (2015) (3)
- Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study. (2022) (3)
- CHAPTER 8 – Lipoprotein Oxidation and Modification (2009) (3)
- Effects of Mixed Nut Consumption on LDL Cholesterol and Lipoprotein(a) in Overweight and Obese Adults (2020) (3)
- Abstract 4998: Elevated Oxidized Phospholipids on Apolipoprotein B-100 Particles Predict 6-Year Cardiovascular Events in the Epic-Norfolk Study: Potentiation of Risk with Lipoprotein-Associated (Lp-PLA2) and Soluble Phospholipase A2 (sPLA2) Activity (2008) (3)
- Highly Sensitive to Their Regression Provides an Accurate Measure of Atherosclerotic Lesions Rich in Oxidized LDL and Is In Vivo Uptake of Radiolabeled MDA 2 , an Oxidation-Specific Monoclonal Antibody (2000) (3)
- Lipoprotein apheresis and acute reduction of arterial inflammation: FDG-PET as an imaging biomarker of nonpharmacological effects on the vessel wall. (2014) (3)
- Highlights of the Year in JACC 2011. (2012) (3)
- Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering (2022) (2)
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. Reply. (2020) (2)
- Lipoprotein(a) and CT Angiography: Novel Insights Into High-Risk Plaque Progression. (2022) (2)
- Highlights of the year in JACC 2004. (2005) (2)
- Trends in Testing for Lipoprotein(a) at an Academic Medical Center Over 13 Years (2017) (2)
- Highlights of the Year in JACC 2006. (2007) (2)
- Ancient Remedy for a Modern Disease (2020) (2)
- Rapid progression of common femoral artery stenosis leading to development of ischemic foot ulcer following repeated ipsilateral arterial access (2005) (2)
- HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a)1 (2015) (2)
- Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency (2009) (2)
- POTENT ANTISENSE OLIGONUCLEOTIDES TO APO(A) NORMALIZE PLASMA LP(A) LEVELS IN THE MAJORITY OF PEOPLE WITH ELEVATED LP(A): RESULTS OF ISIS-APO(A)RX PHASE 2 AND ISIS-APO(A)-LRX PHASE 1 TRIALS (2016) (2)
- THE EFFECT OF HIGH DOSE STATIN THERAPY ON LIPOPROTEIN-ASSOCIATED AND SECRETORY PHOSPHOLIPASE A2 MASS AND ACTIVITY AND ISCHEMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES (2010) (2)
- Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease (2015) (2)
- Emerging Biomarkers of Instability (2007) (2)
- Statin therapy and secretory phospholipase A₂ in children with heterozygous familial hypercholesterolemia. (2013) (2)
- Abstract 14697: Novel Assays for Quantification of Lipoprotein-Associated (PCSK9-apoB, PCSK9-Lp(a)) Proprotein Covertase Subtilisin/Kexin Type 9 (PCKS9) (2015) (2)
- Highlights of the Year in JACC 2009. (2010) (2)
- Mechanical disruption of atherosclerotic plaques during percutaneous coronary intervention results in acute plasma increases in oxidized low-density lipoprotein and Lp(a): Implications for understanding vulnerable plaques (2003) (1)
- Erratum: A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma (2019) (1)
- Successful treatment of in-stent restenosis of a covered stent graft with a paclitaxel-eluting stent. (2011) (1)
- Panel Discussion (2006) (1)
- AGED GARLIC EXTRACT WITH SUPPLEMENT SLOWED THE PROGRESSION OF METABOLICALLY ACTIVE EPICARDIAL ADIPOSE TISSUE, INFLAMMATION AND CORONARY ATHEROSCLEROSIS: A RANDOMIZED CLINICAL TRIAL (2012) (1)
- Abstract 14351: Increased Levels of IgM Autoantibodies to Oxidation-Specific Epitopes are Inversely Associated With Coronary Heart Disease: Analyses of Data From 204,257 Participants (2015) (1)
- LDL-cholesterol corrected for LP(A)-cholesterol, risk thresholds and cardiovascular events (2020) (1)
- INFECTIONS, IMMUNITY AND ATHEROSCLEROSIS: ASSOCIATIONS OF ANTIBODIES TO OXIDIZED LDL AND INFECTIOUS AGENTS IN THE BRUNECK STUDY (2004) (1)
- chapter 21 – Molecular Biology of Lipoproteins and Dyslipidemias (2004) (1)
- Abstract 664: Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio with Concomitant Depletion of Oxidized Phospholipids from Atherosclerotic Lesions Following Dietary Lipid Lowering: A Potential Biomarker of Early Atherosclerosis Regression (2006) (1)
- Abstract 838: Heritability Of Oxidized Phospholipids And Lp(a): Studies In Twin Pairs (2008) (1)
- Abstract 13913: Single Dose Safety, Pharmacokinetics, and Pharmacodynamics of a Potent PCSK9 Synthesis Inhibitor, AZD8233, in Subjects With Elevated Ldl Cholesterol (2020) (1)
- Abstract 16597: Peptides Isolated From a Peptide Phage Display Library Mimic an Epitope of MDA-LDL and Apoptotic Cells and Are Recognized by Human Autoantibodies (2011) (1)
- Highlights of the year in JACC 2010. (2011) (1)
- Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents (2021) (1)
- The role of lipoprotein(a) in progression of renal disease: Causality or reverse causality? (2016) (1)
- Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA (2022) (1)
- Oxidized phospholipids on lipoprotein(a) induce epigenetic reprogramming and an increased pro-atherogenic response in human monocytes. (2017) (1)
- RENAL ARTERY PLAQUE COMPOSITION IS ASSOCIATED WITH CHANGE IN RENAL PERFUSION FOLLOWING RENAL ARTERY STENTING (2010) (1)
- Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers (2020) (1)
- Unmet Needs in Understanding Lipoprotein(a) Pathophysiology: NHLBI Working Group Recommendations to Reduce Risk of Cardiovascular Disease and Aortic Stenosis (2018) (1)
- Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). (2023) (1)
- Highlights of the year in JACC 2003. (2003) (1)
- 4P-0998 Pathophysiologic interrelationship of OxLDL and Lp(a) in human coronary plaque disruption and acute coronary syndromes (2003) (1)
- Highlights of the year in JACC 2007. (2008) (1)
- Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. (2022) (1)
- TCT-555 Release of Bioactive Lipids During Percutaneous Coronary, and Peripheral Arterial Interventions in Humans: Lipidomic analysis of Distal Embolic Protection Devices (2012) (1)
- ELEVATED LEVELS OF OXIDIZED PHOSPHOLIPIDS ON APOLIPOPROTEIN B-100 PREDICT RECURRENT CEREBROVASCULAR EVENTS: A STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS (SPARCL) SUBSTUDY (2015) (1)
- Abstract 14669: Prevalence of Elevated Lp(a) Levels in 629,858 Subjects From a Referral Laboratory Population in the United States (2015) (1)
- Elevated Lp(a) and Abdominal Aortic Aneurysm (2017) (1)
- EFFECT OF IONIS-AGT-LRX, AN ANTISENSE INHIBITOR OF ANGIOTENSINOGEN PRODUCTION, IN HEALTHY VOLUNTEERS AND IN SUBJECTS WITH HYPERTENSION: RESULTS OF PHASE 1 AND PHASE 2 STUDIES (2021) (1)
- OXIDATION-SPECIFIC BIOMARKERS AND PROSPECTIVE 15-YEAR CARDIOVASCULAR AND STROKE OUTCOMES (2012) (1)
- DEDICATED PROGRAM TO ENHANCE MEASUREMENT OF LIPOPROTEIN(A) AMONG PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT (2018) (1)
- Abstract 1454: Targeted Molecular Imaging Probes For In Vivo MR Detection Of Atherosclerotic Lesions Using Antibodies Against Oxidized Low Density Lipoprotein (2007) (1)
- The Effect Of Metabolic Surgery On Lipoprotein(A), Oxidised Phospholipids And Biomarkers Of Lipoprotein Oxidation (2019) (1)
- REMOVING THE LIPOPROTEIN(A)-CHOLESTEROL FROM THE LDL-C MEASUREMENT RESULTS IN A 38% REDUCTION IN PREVALENCE OF ELEVATED LDL-C AT ANY THRESHOLD: IMPLICATIONS FOR THE PREVALENCE AND DIAGNOSIS OF LDL-MEDIATED RISK (2018) (1)
- Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. (2023) (1)
- E06, A NATURAL ANTIBODY TARGETED TO OXIDIZED PHOSPHOLIPIDS, ATTENUATES CARDIAC ISCHEMIA REPERFUSION INJURY IN MICE (2018) (1)
- Combination of sPLA2 activity and cardiovascular risk factors OxPL / apoB for diagnosis / prognosis of a disease / cardiovascular event (2009) (0)
- In vivo plaque uptake of 125I-MDA2, an oxidation-specific monoclonal antibody, detects depletion of oxidized LDL from atherosclerotic lesions (1999) (0)
- Lipoprotein(a) and LDL-C: The Relevance of Equivalence. (2022) (0)
- Molecular Imaging of Oxidation-Specific Epitopes to Detect High-Risk Atherosclerotic Plaques (2015) (0)
- Rationale and design of a clinical trial to assess Lp(a) lowering with ionis-apo(a)-LRX in patients undergoing apheresis for elevated Lp(a) and recurrent cardiovascular events (2016) (0)
- Preferential uptake of radiolabeled oxidation-specific antibodies in lipid-rich versus collagen-rich lesions: Implications for noninvasive imaging of vulnerable plaques (2003) (0)
- Lipoprotein(a) improves cardiovascular risk prediction based on the ACC/AHA and score algorithms in intermediate risk patients; the EPIC-Norfolk prospective population study. (2017) (0)
- Lipoprotein(a) Protects against Oxidized Phospholipid in the Retina (2012) (0)
- PRO-INFLAMMATORY INTERLEUKIN-1 GENOTYPES AFFECT THE ASSOCIATION OF C-REACTIVE PROTEIN FOR ANGIOGRAPHICALLY DETERMINEDCORONARY ARTERY DISEASE AND CARDIOVASCULAR EVENTS (2017) (0)
- Effects of low‐fat, high‐carbohydrate diet on plasma lipoprotein(a) and oxidized phospholipids (2010) (0)
- Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression. (2023) (0)
- Biological significance of autoantibodies to oxidative neoepitopes (2000) (0)
- APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia (2023) (0)
- EFFECT OF UNCOMPLICATED PCI ON PLASMINOGEN AND OXIDIZED PHOSPHOLIPIDS PRESENT ON PLASMINOGEN IN PATIENTS WITH STABLE ANGINA (2013) (0)
- Secrete Atheroprotective IgM and Attenuate Atherosclerosis (2015) (0)
- Insulin Resistance Is Associated With Impaired HDL Function and Atherogenic Modification of LDL in Polycystic Ovarian Syndrome (2021) (0)
- What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)? (2023) (0)
- Chapter 2 LIPOPROTEINS AND OXIDATION (2006) (0)
- Tracking oxidatively stressed cardiac stem cells with molecular imaging: "insights" into fate, viability, and function. (2013) (0)
- 04 - REDUCTION IN AUTOANTIBODIES TO OXIDISED LDL AND APOB-IMMUNE COMPLEXES FOLLOWING METABOLIC SURGERY (2019) (0)
- Abstract 475: Relationship Between Oxidized Phospholipid Content On Apolipoprotein B-100 Particles, Statin Therapy and Atheroma Volume: Observations From The REVERSAL Study (2007) (0)
- P5457Lipoprotein(a) is associated with increased calcification and disease progression in aortic stenosis patients (2018) (0)
- NOVEL BIOMARKERS FOR CRITICAL LIMB ISCHEMIA: ROLE OF ADVANCED GLYCATION ENDPRODUCTS (2013) (0)
- Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: En attendant Godot. (2010) (0)
- Defining the mechanism of lipoprotein(a) [Lp(a)] lowering by alirocumab in transgenic mouse models (2016) (0)
- HIGHLIGHTS FROM JACC IN 2004 Highlights of the Year in JACC 2004 (2005) (0)
- 4P-0970 Phosphorylcholine containing oxidized phospholipids, detected by monoclonal antibody EO6, are transported by Lp(a): A novel function for Ip(a) (2003) (0)
- Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. (2023) (0)
- LDL-C CORRECTED FOR DIRECTLY MEASURED LIPOPROTEIN(A)-CHOLESTEROL IN PATIENTS TREATED WITH LIPOPROTEIN APHERESIS (2022) (0)
- Progressive Atherosclerosis and Incident Cardiovascular Disease Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism Is Associated With (2014) (0)
- Lipoprotein(A) Predicts Cardiovascular Events In Statin Outcome Trials: Pooled Analysis Of Seven Randomised Controlled Trials (2019) (0)
- P5322Oxidized phospholipids on apolipoprotein B-100 among black US adults with and without PCSK9 loss-of-function variants (2019) (0)
- Expression of E06, a natural monoclonal antibody targeted to oxidized phospholipids (OXPL), attenuates the progression of aortic sclerosis in aged hyperlipidemic mice (2016) (0)
- Nuclear imaging of the vulnerable plaque (2007) (0)
- Abstract 14163: Oxidized Phospholipids and Lipoprotein-Associated Phospholipase A2 in Plasma, ApoB-containing and ApoAI -containing Lipoprotein Subfractions in Patients with Familial Hypercholesterolemia: Effect of LDL Apheresis (2010) (0)
- Molecular imaging of MMP expression in atherosclerosis in transgenic mouse models (2008) (0)
- Abstract 495: High-Density Lipoprotein-Mediated Modulation of Autoimmunity in Normolipidemic Lupus-Prone Mice (2012) (0)
- Highlights of the Year in JACC2005 (2016) (0)
- A greek diet raises oleic acid levels and inhibits LDL oxidation (1996) (0)
- WO12-OR-6 LECITHIN:CHOLESTEROL ACYLTRANSFERASE AND PROTECTION AGAINST OXIDATIVE MODIFICATION OF LDL IN CARRIERS OF LCAT GENE MUTATIONS (2007) (0)
- Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP pathways in macrophages (2017) (0)
- P1761Diabetic status influences the effect of pro-inflammatory interleukin-1 genotypes on lipoprotein(a) mediated risk of coronary artery disease and cardiovascular events (2017) (0)
- The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis (2023) (0)
- Abstract 361: Oxidized Phospholipids Are Proinflammatory and Proatherogenic (2016) (0)
- Familial Hypoalphalipoproteinemia Consequences of Cholesteryl Ester Transfer Protein Inhibition in Patients With (2011) (0)
- Oxidized LDL autoantibodies, chronic infections and carotid atherosclerosis (2006) (0)
- Abstract 11456: Elevated Lipoprotein(a) is Associated with Statin Resistance (2021) (0)
- Edinburgh Explorer Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis (2019) (0)
- Abstract 15: The Helix-Loop-Helix Factor Id3 Links Natural Helper Cells to Proliferation of Atheroprotective B-1a Cells (2013) (0)
- Abstract 29: PCSK9 Association With Lipoprotein(a) (2015) (0)
- LIPOPROTEIN(A)-CHOLESTEROL (LP(A)-C) LEVELS DETERMINED BY VERTICAL AUTO PROFILE (VAP) CORRELATES WEAKLY WITH LP(A) MASS IN HYPERCHOLESTEROLEMIC SUBJECTS (2016) (0)
- Edinburgh Research Explorer Secretory Phospholipase A2-IIA and Cardiovascular Disease (2018) (0)
- Residual inflammatory risk increases endothelial metabolism, thereby facilitating sustained vascular inflammation and leukocyte extravasation (2021) (0)
- Abstract 11339: Relationship of LPA Single Nucleotide Polymorphisms With Apolipoprotein (a) Isoforms and Biomarkers of Oxidized Lipoproteins in African-Americans, Caucasians and Hispanics: Results From the DALLAS Heart Study (2015) (0)
- Abstract 2950: Imaging of Matrix Meralloproteinase Expression in Atherosclerotic Lesions in apolipoprotein E-deficient and Low-density-lipoprotein Receptor-deficient Mice (2007) (0)
- Abstract 11174: Effect of APOCIII-L Rx on Lipoprotein Size and Particle Numbers Measured by NMR in Patients with Hypertriglyceridemia: Results of the AKCEA-APOCIII-L Rx Trial (2021) (0)
- Coronary Heart Disease Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes (2012) (0)
- Lipoprotein(a)-cholesterol (Lp(a)-C) levels determined by vertical auto profile (VAP) correlates weakly with Lp(a) mass but modestly with HDL-C: Implications for appropriate interpretation of clinical data (2016) (0)
- Abstract MP04: Single Cell Profiling Identifies IgM To MDA-LDL Producing Human B Cells And Atheroprotective Role Of CD24 (2021) (0)
- Single cell profiling identifies IgMMDA-LDL-producing human B cells and a novel role for CD24 (2021) (0)
- HDL compartmentalisation regulates PCSK9 activity (2021) (0)
- Lipoprotein(A) is associated with increased calcification and disease progression in aortic stenosis patients (2018) (0)
- Oxidized phospholipids, Lp(a) and coronary heart disease risk (2012) (0)
- Genetic Testing in Patients with High Lipoprotein(a): Experience from the UCSD Lipoprotein(a) Specialty Clinic (2020) (0)
- Abstract 90: The Atheroprotective Effects of Id3 Are Linked to B-1a Cell Proliferation and Plasma Levels of E06 (2012) (0)
- Reduction Of Plasma Lipoprotein(A) With Antisense Oligonucleotides In Human Subjects Does Not Affect Fibrinolysis (2019) (0)
- Noninvasive imaging and quantitation of atherosclerosis with radiolabeled oxidation-specific antibodies (2000) (0)
- Abstract P248: Oxidized Phospholipids and Risk of Peripheral Arterial Disease in Men (2012) (0)
- Lipoprotein(A), Oxidized Phospholipids, And Aortic Valve Microcalcification Assessed By 18f-Naf Pet/Ct (2019) (0)
- Inhibition of novel lipoprotein(a) receptor major facilitator superfamily domain containing 5 (MFSD5) reduces development of aortic valve calcification (2022) (0)
- Glucose Control in Patients Undergoing PCI: What Is the Optimal HbA1c for Long-Term Outcomes? (2021) (0)
- Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification. (2023) (0)
- Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects. (2022) (0)
- Clinical Trial Report: The Presence and Rupture of Vulnerable Plaques in the Peripheral Circulation (2010) (0)
- P010. Evaluation of the Efficacy and Safety of AKCEA-TTR-LRx (ION-682884) in Patients with Transthyretin-mediated Amyloid Cardiomyopathy: The CARDIO-TTRansform Study (2021) (0)
- Subject Index Vol. 25, 2007 (2007) (0)
- DEFINING THE MECHANISM OF LP(A) LOWERING BY ALIROCUMAB IN TRANSGENIC MOUSE MODELS (2016) (0)
- RELATIONSHIP OF BIOMARKERS OF OXIDIZED LIPOPROTEINS TO ETHNICITY, SUBCLINICAL ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS OVER A 10.5 YEAR FOLLOW-UP IN THE DALLAS HEART STUDY (2017) (0)
- Natural temporal variability in Lp(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx antisense oligonucleotide clinical trials (2016) (0)
- FROM JACC IN 2004 ighlights of the Year in JACC 2004 (2016) (0)
- Abstract 490: Distribution of Oxidized Phospholipids and Lipoprotein-Associated Phospholipase A2 in Plasma, Density Gradient Fractions and Individual Lipoproteins in Patients with Familial Hypercholesterolemia: Effect of LDL Apheresis (2012) (0)
- Role of Oxidized Phospholipids in Cardiovascular Disease (2015) (0)
- Abstract 205: Protective Role for B-1 B Cells and IgM Antibodies in Obesity (2014) (0)
- Abstract 235: Prevalence of Lipoprotein(a) Measurements and Extent of Lipoprotein(a) Elevations in 2,266 Patients with Aortic Stenosis: Results from an Academic Echocardiography Laboratory Practice Setting (2016) (0)
- RATIONALE AND DESIGN OF THE BALANCE STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF OLEZARSEN IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (2023) (0)
- FRS-020 Annexin-A5 Uptake Verified Apoptosis in Transgenic ApoE- and LDLR-Knockout Mice With and Without Cholesterol Diet(Advances in Nuclear Cardiology-1 (I) FRS4,Featured Research Session,The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society) (2006) (0)
- Abstract 14013: Lipoprotein-Associated Phospholipase A2 Mass and Activity in Children with Heterozygous Familial Hypercholesterolemia: Effect of Pravastatin and Relationship to Carotid Intima Media Thickness (2010) (0)
- Abstract 12329: Novel High-Throughput ELISAs to Measure ApoC-III on ApoB-100, ApoA-I and Lp(a): Reduction in Lipoprotein-Associated ApoC-III Levels With Volanesorsen (ISIS-APOC-IIIRx) Antisense Therapy to ApoC-III in a Phase 2 Randomized Trial (2015) (0)
- EFFECT OF IONIS-AGT-LRX IN SUBJECTS WITH UNCONTROLLED HYPERTENSION ON 2-3 MEDICATIONS: RESULTS OF A PHASE 2 STUDY (2021) (0)
- Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis. (2023) (0)
- Contents Vol. 25, 2007 (2007) (0)
- Always Present, But Now Rediscovered: Lp(a) as a Predictor of Long-Term Outcomes in PCI. (2021) (0)
- Targeting Lipoprotein(A)-Induced Endothelial Cell Metabolic Reprogramming Reverses Inflammation And Leukocyte Migration (2019) (0)
- Integrated Assessment of Phase 2 Data on GalNAc3-Conjugated 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides. (2022) (0)
- Oxidation-specific epitopes restrain bone formation (2018) (0)
- Abstract 3625: Targeted Ultra-Small Iron Oxide Particles for In Vivo MR Detection of Atherosclerotic Lesions Using Antibodies against Oxidized Low Density Lipoprotein (2008) (0)
- Divergent Changes In Lipoprotein(A) And Oxidised Phospholipids Following Metabolic Surgery (2019) (0)
- Author response for "A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow‐Fed Young Adult Mice" (2020) (0)
- TRENDS IN TESTING AND PREVALENCE OF ELEVATED LIPOPROTEIN(A) AMONG PATIENTS WITH AORTIC VALVE STENOSIS (2022) (0)
- Reduction In Autoantibodies To Oxidised Ldl And Apob-Immune Complexes Following Metabolic Surgery (2019) (0)
- 763 EFFECT OF MIPOMERSEN ON LP(A) IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; RESULTS FROM TWO PHASE 3 STUDIES E. Steinhaqen-Thiessen (2011) (0)
- Abstract P801: Impact of Oxidized Phospholipids on Outcomes From Cerebral Ischemia and Reperfusion Injury (2021) (0)
- Prevalence of LPA single nucleotide polymorphisms and isoforms in patients enrolled in a phase 2 IONIS-APO(a)Rx clinical trial (2016) (0)
- OXIDIZED PHOSPHOLIPID, LIPOPROTEIN(A), AND AORTIC VALVE CALCIFICATION: A POOLED ANALYSIS OF THE FRAMINGHAM HEART STUDY AND THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (2020) (0)
- Interventional hepatic ApoC-III knockdown improves atherosclerotic plaque stability and remodeling via lowering remnant lipoproteins (2021) (0)
- Apolipoprotein C-III: From Pathophysiology to (2015) (0)
- Targeted Iron Oxide Particles For In Vivo MR Detection of Atherosclerotic Lesions Using Antibodies against Oxidized Low Density Lipoprotein : Effect of Particle Size (2009) (0)
- Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation (2022) (0)
- Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice (2018) (0)
- Abstract 18477: Understanding the Causal Relevance of Apo(a) Isoform Size, Lipoprotein (a) and Oxidized Phospholipids in Coronary Heart Disease (2016) (0)
- Abstract 417: CXCR4 Distinguishes and Maintains Atheroprotective IgM-producing B-1 cells (2018) (0)
- Effects of pitavastatin therapy on glucose, HBA1C and incidence of diabetes mellitus: A meta-analysis of randomized controlled clinical trials in non-diabetic individuals (2015) (0)
- Abstract 14911: Induction Of Regression Of Atherosclerosis By The LXR-agonist R211945-a Multimodality Non-invasive Assessment And Comparison With Atorvastatin (2011) (0)
- Abstract 2195: Non-Invasive Imaging of Atherosclerotic Lesions in Apolipoprotein E-Deficient and Low Density Lipoprotein Receptor-Deficient Mice With Annexin A5 (2006) (0)
- xidized Low-Density Lipoprotein utoantibodies , Chronic Infections , and arotid Atherosclerosis in a Population-Based Study (2006) (0)
- Abstract 197: Characterization of the Effects of Angiopoietin-Like 3 on Plasma Lipids and Lipoproteins in Humans (2017) (0)
- Abstract 223: CXCR4 Regulates B1 Cell Localization, Proliferation, Survival, and Atheroprotective IgM Production (2017) (0)
- Imaging of neovascularization in atherosclerotic plaque with 99mTc-labeled single chain VEGF: Proof of concept for imaging vulnerable plaque (2007) (0)
- Plasma apolipoprotein CIII levels and incident coronary artery disease risk: The EPIC-Norfolk prospective population study (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sotirios Tsimikas?
Sotirios Tsimikas is affiliated with the following schools:
- University of Amsterdam
- Medical University of Vienna
- Taipei Medical University
- University of Oxford
- Medical University of Innsbruck
- University of California, San Diego
- University of Ioannina
- Stanford University
- University of Massachusetts Medical School
- University of Virginia
- University of California, San Francisco
